US 11267896
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 11267896 (Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 34
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K47/6803, A61K47/68031